Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study

Abstract

Aim: Evaluation of the anti-aging properties of Empagliflozin (EMP) associated with the aging process in mice. Methods: The mice were allocated into four groups: negative control received normal saline without receiving D-galactose (DGA); all the three other groups received DGA (200 mg/kg/day orally) for eight weeks; the second group received normal saline; the third group received vitamin C, the final group received EMP and continued for another eight weeks. Results: Treatment with EMP reduced the levels of TNF-α, IL-1β, and MDA levels significantly compared to induction group (91.7±9.6 ng/ml, 30.6±5.5 pg/ml, and 66.7±8.3 ng/ml vs. 304.0±102.9 ng/ml, 70.2±6.8 pg/ml, and 204.7±56.9 ng/ml; respectively), while levels of GSH-Px were significantly increased (3.3±0.6 ng/ml vs. 0.3±0.2 ng/ml). In addition, EMP increases the level of both COL-1 and COL-3 compared to the induction group (1,783.6±186.9, and 1,583.6±186.9, vs. 885.7±242.5, and 685.7±242.5 pg/ml; respectively). Conclusion: EMP positively affects several aging parameters in mice.